Brief: Briacell Therapeutics Corp Announces New Patent Issuance, Bria-Ots IND Timing Guidance, And Additional Clinical Sites To Boost Enrolment
10/01/2023 14:07
Jan 10 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL ANNOUNCES NEW PATENT ISSUANCE, BRIA-OTS™ IND
TIMING
GUIDANCE, AND ADDITIONAL CLINICAL SITES TO BOOST ENROLMENT
* BRIACELL THERAPEUTICS CORP - EXPECTS TO INITIATE ITS
BRIA-OTS™
CLINICAL STUDY UNDER AN INVESTIGATIONAL NEW DRUG APPLICATION IN
FIRST HALF OF 2023
Source text for Eikon: ID:nGNX7bhL5r
Further company coverage: BCT.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study